Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Alvimopan (also known as ADL 8-2698; LY 246736; HSDB-7704) is a novel peripheral micro opioid antagonist in clinical development for the management of post-operative ileus and opioid-induced bowel dysfunction. Alvimopan acts for a longer period of time than other antagonists that act more quickly, which may be connected to a slower rate of dissociation from the micro opioid receptor. In comparison to the long-acting partial agonist buprenorphine (t(1/2)=44 min), alvimopan's dissociation rate from the micro opioid receptor (t(1/2)=30–44 min) was slower than that of the antagonists naloxone (t(1/2)=0.82 min) and N-methylnaltrexone (t(1/2)=0.46 min). Moreover, after preincubation with the micro opioid receptor, increases were seen in the apparent affinities and potencies of buprenorphine and alvimopan, but not of naloxone or methylnaltrexone. Alvimopan does not dissociate from the micro opioid receptor as quickly as other drugs that act more quickly, which is consistent with its prolonged duration of action.
Targets |
μ-opioid receptor ( Ki = 0.77 nM ); δ-opioid receptor ( IC50 = 4.4 nM ); δ-opioid receptor ( Ki = 4.4 nM ); κ-opioid receptor ( Ki = 40 nM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Enzyme Assay |
Alvimopan has a more modest (≥6-fold) μ/δ receptor selectivity, but is highly selective (by ≥227-fold) for the human μ receptor over the κ subtype. Alvimopan has pA2 values of 9.6 or 9.7 and is a strong antagonist of morphine, DAMGO or endomorphin-1-induced, and μ opioid receptor-mediated electrically evoked contraction inhibition in the isolated ileum of guinea pigs. The ileum of guinea pigs has lower alvimopan antagonist potencies (δ and κ antagonists, with pA2 values of 8.7 and 7.8, respectively). Tested at both 1 and 10 μM, alvimopan does not exhibit any noteworthy affinity for a wide variety of non-opioid receptors, ion channels, or enzymes.
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C25H32N2O4
|
---|---|
Molecular Weight |
424.54
|
Exact Mass |
424.24
|
Elemental Analysis |
C, 70.73; H, 7.60; N, 6.60; O, 15.07
|
CAS # |
156053-89-3
|
Related CAS # |
Alvimopan dihydrate; 170098-38-1; Alvimopan monohydrate; 1383577-62-5
|
Appearance |
Solid powder
|
SMILES |
O=C(O)CNC([C@H](CN1C[C@H](C)[C@](C)(C2=CC=CC(O)=C2)CC1)CC3=CC=CC=C3)=O
|
InChi Key |
UPNUIXSCZBYVBB-JVFUWBCBSA-N
|
InChi Code |
InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
|
Chemical Name |
((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoyl)glycine
|
Synonyms |
LY246736; LY246736; LY-246736; HSDB 7704; HSDB7704; HSDB-7704; ADL 8-2698; ADL8-2698; ADL-8-2698; Alvimopan; Brand name Entereg
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3555 mL | 11.7775 mL | 23.5549 mL | |
5 mM | 0.4711 mL | 2.3555 mL | 4.7110 mL | |
10 mM | 0.2355 mL | 1.1777 mL | 2.3555 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04405037 | Recruiting | Drug: Alvimopan | Gastrointestinal Dysfunction Ileus |
Scott Steele | August 1, 2020 | Phase 4 |
NCT03216525 | Completed | Drug: Alvimopan Drug: Placebo |
Ileus Spinal Fusion |
Washington University School of Medicine |
August 2014 | Not Applicable |
NCT02218190 | Completed | Drug: Alvimopan | Migraine | Ortho-McNeil Neurologics, Inc. | June 2004 | Phase 4 |
NCT02789111 | Completed | Drug: Alvimopan Drug: Placebo |
Constipation | University of Virginia | June 1, 2016 | Phase 4 |
NCT02742181 | Completed | Drug: Alvimopan Other: Control Group |
Colorectal Surgery Ileus |
Sharon Stein | December 2, 2015 | Phase 3 |
Chemical structure of alvimopan (Entereg). P T. 2008 Oct; 33(10): 574, 580-583. td> |
The effects of subcutaneous alvimopan and ADL 08-0011 on morphine-induced slowing of small intestinal transit (assessed with respect to the distance travelled by an orally dosed charcoal meal) and analgesia (hot-plate assay) in mice (n = 6-9), and b) the doses associated with 50% reversal (ID50 values) of morphine-induced responses, with the derived peripheral selectivities for each compound. Therapeutics. 2009, 1: 199-213. td> |
Hazard ratios (with 95% confidence intervals) for (a) GI-3 and (b) GI-2 recoveries in each of the Phase 3 studies performed with alvimopan (12 mg b.i.d.) in patients undergoing bowel resection. Therapeutics. 2009, 1: 199-213. td> |
Proportion of patients with postoperative morbidity related to POI in each of the Phase 3 studies performed with alvimopan (12 mg b.i.d.) in patients undergoing bowel resection. Therapeutics. 2009, 1: 199-213. td> |